石四药集团(02005)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02005 石四药集团

未开盘 10-14 16:08:26

2.745

+0.015

+0.55%

最高2.770	最低2.690	成交量846.20万
今开2.720	昨收2.730	日振幅2.93%
总市值79.19亿	流通市值79.19亿	总股本28.85亿
成交额2,317万	换手率0.29%	流通股本28.85亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02005","market":"HK","secType":"STK","nameCN":"石四药集团","latestPrice":2.745,"timestamp":1791965306004,"preClose":2.73,"halted":0,"volume":8462000,"delay":0,"changeRate":0.00549450549450554,"floatShares":2885000000,"shares":2885000000,"eps":0.1605,"marketStatus":"未开盘","change":0.015,"latestTime":"10-14 16:08:26","open":2.72,"high":2.77,"low":2.69,"amount":23173674,"amplitude":0.029304,"askPrice":2.755,"askSize":4000,"bidPrice":2.745,"bidSize":32000,"shortable":3,"etf":0,"ttmEps":0.174609,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1792027800000},"marketStatusCode":0,"adr":0,"listingDate":1135008000000,"exchange":"SEHK","adjPreClose":2.73,"dividendRate":0.030929,"openAndCloseTimeList":[[1791941400000,1791950400000],[1791954000000,1791964800000]],"volumeRatio":1.7586446257376653,"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02005/tweets","defaultTab":"tweets","newsList":[{"id":"1128071781","title":"石四药集团（02005.HK）获批尼莫地平口服溶液生产注册　完善心脑血管及神经重症产品布局","url":"https://stock-news.laohu8.com/highlight/detail?id=1128071781","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1128071781?lang=zh_cn&edition=full","pubTime":"2026-10-08 16:42","pubTimestamp":1791448922,"startTime":"0","endTime":"0","summary":"石四药集团有限公司10月8日发布自愿公告称，公司已取得中国国家药品监督管理局核发的“尼莫地平口服溶液”药品生产注册批件。公告显示，尼莫地平口服溶液主要用于治疗因颅内囊性动脉瘤破裂导致蛛网膜下腔出血的成人患者，可通过降低缺血性神经损伤的发生率和严重程度来改善神经系统预后。石四药集团此前于2025年3月19日公告，其尼莫地平原料药已获国家药监局批准登记为上市制剂所用原料药。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123694506","title":"石四药集团：China Pharmaceutical Company Limited增持，好仓比例升至31.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=1123694506","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123694506?lang=zh_cn&edition=full","pubTime":"2026-10-02 17:42","pubTimestamp":1790934174,"startTime":"0","endTime":"0","summary":"China Pharmaceutical Company Limited于2026年10月2日以每股均价2.7696港元场外买入石四药集团（02005）50.00万股，涉资约138.48万港元。该笔为场外交易（自愿披露），未经联交所公开市场撮合，不属二级市场直接买卖。China Pharmaceutical Company Limited此次增持前持有石四药集团好仓9.25亿股，占比31.33%；增持后持股量为9.25亿股，好仓比例升至31.35%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180478572","title":"石四药集团公布9月股份变动月报表，回购655万股转为库存","url":"https://stock-news.laohu8.com/highlight/detail?id=1180478572","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1180478572?lang=zh_cn&edition=full","pubTime":"2026-10-02 17:41","pubTimestamp":1790934108,"startTime":"0","endTime":"0","summary":"石四药集团于2026年10月2日发布2026年9月股份变动月报表。该报告期为截至2026年9月30日，反映了公司在9月份的股本结构和股份变动情况。9月内，公司回购6,550,000股并将其全数转为库存。截至9月底，已发行股份数量变更为2,884,893,385股，库存股份增至66,220,000股，总股本仍维持在2,951,113,385股。自本次回购后，截至2026年9月30日，石四药集团的股本总数仍保持不变。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108543116","title":"石四药集团：China Pharmaceutical Company Limited增持，好仓比例升至31.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=1108543116","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1108543116?lang=zh_cn&edition=full","pubTime":"2026-09-29 17:50","pubTimestamp":1790675432,"startTime":"0","endTime":"0","summary":"China Pharmaceutical Company Limited于2026年9月29日以每股均价2.7812港元场外买入石四药集团（02005）股份150.00万股，涉资约417.18万港元。该笔交易为场外交易，未经联交所公开市场撮合，不属二级市场直接买卖。China Pharmaceutical Company Limited此次增持前持有石四药集团好仓9.23亿股，占比31.28%；增持后持股量为9.25亿股，好仓比例升至31.33%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154407258","title":"石四药集团(02005)公布董事会及三大委员会成员名单","url":"https://stock-news.laohu8.com/highlight/detail?id=1154407258","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154407258?lang=zh_cn&edition=full","pubTime":"2026-09-28 19:22","pubTimestamp":1790594528,"startTime":"0","endTime":"0","summary":"石四药集团有限公司于2026年9月28日发布公告，披露公司董事会及其下属三大委员会最新成员组成情况。公告显示，董事会由执行董事、非执行董事及独立非执行董事共九名成员组成。执行董事兼主席兼行政总裁为曲继广；其他执行董事为孟国、周兴扬、曲婉蓉和吴恒耀。独立非执行董事包括王亦兵、周国伟及姜广策。公告称，上述安排自公布之日起生效。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123940789","title":"石四药集团任命吴恒耀为执行董事 苏学军同日辞任","url":"https://stock-news.laohu8.com/highlight/detail?id=1123940789","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123940789?lang=zh_cn&edition=full","pubTime":"2026-09-28 19:16","pubTimestamp":1790594189,"startTime":"0","endTime":"0","summary":"石四药集团有限公司9月28日发布董事局公告称，自2026年9月28日起：吴恒耀先生获委任为执行董事；苏学军先生因专注其他工作安排辞任执行董事。吴恒耀，57岁，现任公司全资附属公司新东投资医药控股（香港）有限公司及石家庄四药有限公司董事，并担任石家庄四药总裁。截至公告日期，董事局成员包括执行董事曲继广、孟国、周兴扬、曲婉蓉及吴恒耀；非执行董事刘文军；独立非执行董事王亦兵、周国伟及姜广策。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670231616","title":"石四药集团(02005)：吴恒耀获委任为执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2670231616","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670231616?lang=zh_cn&edition=full","pubTime":"2026-09-28 19:14","pubTimestamp":1790594092,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石四药集团(02005)发布公告，自2026年9月28日起：1.吴恒耀先生获委任为执行董事;及2.苏学军先生因有意专注彼的其他工作安排而辞任执行董事。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1501628.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02005","BK1191","LU2460026573.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182313545","title":"石四药集团：曲继广增持，好仓比例升至43.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=1182313545","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1182313545?lang=zh_cn&edition=full","pubTime":"2026-09-25 17:51","pubTimestamp":1790329869,"startTime":"0","endTime":"0","summary":"根据披露，曲继广于2026年9月25日在联交所场内以每股均价2.7695港元买入石四药集团50.00万股，涉资约138.47万港元。该笔交易属场内主动交易，即在二级市场直接买卖股份。曲继广此次增持前持有石四药集团好仓12.80亿股，占比43.37%；增持后持股量为12.81亿股，好仓比例升至43.39%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108089059","title":"石四药集团：China Pharmaceutical Company Limited增持，好仓比例升至31.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=1108089059","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1108089059?lang=zh_cn&edition=full","pubTime":"2026-09-25 17:15","pubTimestamp":1790327711,"startTime":"0","endTime":"0","summary":"China Pharmaceutical Company Limited于2026年9月25日以每股均价2.7695港元场外买入石四药集团（02005）股份50.00万股，涉资约138.47万港元。该笔为场外交易（代价性质未注明），未经联交所公开市场撮合，不属二级市场直接买卖。China Pharmaceutical Company Limited此次增持前持有石四药集团好仓9.23亿股，占比31.26%；增持后持股量为9.23亿股，好仓比例升至31.28%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177675298","title":"石四药集团：曲继广增持，好仓比例升至43.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=1177675298","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1177675298?lang=zh_cn&edition=full","pubTime":"2026-09-24 17:22","pubTimestamp":1790241753,"startTime":"0","endTime":"0","summary":"曲继广于2026年9月24日在联交所场内以每股均价2.7928港元买入石四药集团股份70.00万股，涉资约195.50万港元，属场内主动交易，即在二级市场直接买卖股份。曲继广此次增持前持有石四药集团好仓12.79亿股，占比43.35%；增持后持股量为12.80亿股，好仓比例升至43.37%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195536456","title":"石四药集团回购70万股股份，总额约195.50万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1195536456","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1195536456?lang=zh_cn&edition=full","pubTime":"2026-09-24 16:37","pubTimestamp":1790239054,"startTime":"0","endTime":"0","summary":"石四药集团有限公司于2026年9月24日发布公告，披露已在香港联合交易所场内回购普通股股份。本次回购基于此前董事会授权进行。本次回购股份数量为700,000股，占交易日前已发行股本约0.024%，每股回购价介乎2.78港元至2.80港元，合计支付价格1,954,950港元，折合约195.50万港元。回购完成后，公司已发行股本总数下降至2,884,893,385股，库藏股上升至66,220,000股，总股本维持在2,951,113,385股。本公告由石四药集团有限公司执行董事兼公司秘书周兴扬签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"石四药集团回购70万股股份，总额约195.50万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669463588","title":"石四药集团(02005)9月24日斥资195.5万港元回购70万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2669463588","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669463588?lang=zh_cn&edition=full","pubTime":"2026-09-24 16:32","pubTimestamp":1790238735,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石四药集团(02005)发布公告，于2026年9月24日斥资195.5万港元回购70万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1500435.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2460026573.USD","02005","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180553474","title":"石四药集团：曲继广增持，好仓比例升至43.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=1180553474","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1180553474?lang=zh_cn&edition=full","pubTime":"2026-09-23 17:50","pubTimestamp":1790157042,"startTime":"0","endTime":"0","summary":"曲继广于2026年9月23日通过其控制的公司在联交所场内以每股均价2.797港元买入石四药集团125.00万股，涉资约349.62万港元，属场内主动交易，即在二级市场直接买卖股份。曲继广此次增持前持有石四药集团好仓12.78亿股，占比43.31%；增持后持股量为12.79亿股，好仓比例升至43.35%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118164241","title":"石四药集团：China Pharmaceutical Company Limited增持，好仓比例升至31.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=1118164241","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118164241?lang=zh_cn&edition=full","pubTime":"2026-09-23 17:12","pubTimestamp":1790154734,"startTime":"0","endTime":"0","summary":"China Pharmaceutical Company Limited于2026年9月23日以每股均价2.7970港元场外买入125.00万股石四药集团股份，涉资约349.62万港元，属场外交易（未经联交所公开市场撮合，不属二级市场直接买卖）。该笔交易为自愿披露。China Pharmaceutical Company Limited此次增持前持有石四药集团好仓9.21亿股，占比31.22%；增持后持股量为9.23亿股，好仓比例升至31.26%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176902139","title":"石四药集团：曲继广增持，好仓比例升至43.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=1176902139","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1176902139?lang=zh_cn&edition=full","pubTime":"2026-09-22 17:42","pubTimestamp":1790070137,"startTime":"0","endTime":"0","summary":"曲继广于2026年9月22日在联交所场内以每股均价2.7624港元买入石四药集团股份100.00万股，涉资约276.24万港元，属场内主动交易，即在二级市场直接买卖股份。曲继广此次增持前持有石四药集团好仓12.77亿股，占比43.27%；增持后持股量为12.78亿股，好仓比例升至43.31%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162389697","title":"石四药集团回购100万股股份，总额约276.24万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1162389697","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1162389697?lang=zh_cn&edition=full","pubTime":"2026-09-22 16:56","pubTimestamp":1790067387,"startTime":"0","endTime":"0","summary":"2026年9月22日，石四药集团有限公司发布翌日披露报表称，公司于当日于香港联交所场内回购合计100万股股份，约占本次回购前公司已发行股本的0.035%。每股回购价格介乎港币2.745元至2.77元，总计耗资约2,762,370港元，折合约276.24万港元。本次回购完成后，公司已发行股份由原先的2,886,593,385股减少至2,885,593,385股，同时库藏股由64,520,000股增加至65,520,000股。公司在公告中确认已遵守香港联交所证券上市规则及相关法律法规。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"石四药集团回购100万股股份，总额约276.24万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669117256","title":"石四药集团(02005)9月22日斥资276.24万港元回购100万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2669117256","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669117256?lang=zh_cn&edition=full","pubTime":"2026-09-22 16:50","pubTimestamp":1790067032,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石四药集团(02005)发布公告，该公司于2026年9月22日斥资276.24万港元回购100万股股份，每股回购价格为2.745-2.77港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1499298.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02005","BK1191","LU2460026573.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164573904","title":"石四药集团：曲继广增持，好仓比例升至43.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=1164573904","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1164573904?lang=zh_cn&edition=full","pubTime":"2026-09-21 17:51","pubTimestamp":1789984268,"startTime":"0","endTime":"0","summary":"曲继广于2026年9月21日在联交所场内以每股均价2.7495港元买入石四药集团股份80.00万股，涉资约219.96万港元，属场内主动交易，即在二级市场直接买卖股份。曲继广此次增持前持有石四药集团好仓12.76亿股，占比43.25%；增持后持股量为12.77亿股，好仓比例升至43.27%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124129307","title":"石四药集团回购80万股股份，斥资约220万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1124129307","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1124129307?lang=zh_cn&edition=full","pubTime":"2026-09-21 16:39","pubTimestamp":1789979982,"startTime":"0","endTime":"0","summary":"石四药集团于2026年9月21日公告称，公司于当日在香港联交所场内回购股份80万股，约占回购前公司已发行股本的0.028%。本次回购价格区间为每股2.735港元至2.755港元，合计耗资约219.96万港元。本次回购完成后，公司已发行股份总数仍为2,951,113,385股，其中2,886,593,385股为已发行且未被持作库藏的股份，库藏股数量增至64,520,000股。公司强调，本次操作符合香港联合交易所有限公司证券上市规则及适用法律法规的相关规定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"石四药集团回购80万股股份，斥资约220万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669156029","title":"石四药集团(02005)9月21日斥资219.96万港元回购80万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2669156029","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669156029?lang=zh_cn&edition=full","pubTime":"2026-09-21 16:33","pubTimestamp":1789979637,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石四药集团(02005)发布公告，于2026年9月21日，该公司斥资219.96万港元回购80万股股份，每股回购价2.735-2.755港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1498705.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2460026573.USD","02005","BK1191"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ssygroup.com.hk","stockEarnings":[{"period":"1week","weight":0.0018},{"period":"1month","weight":0.0378},{"period":"3month","weight":0.1033},{"period":"6month","weight":0.1447},{"period":"1year","weight":-0.004},{"period":"ytd","weight":0.0029}],"compareEarnings":[{"period":"1week","weight":0.0076},{"period":"1month","weight":-0.0242},{"period":"3month","weight":-0.0278},{"period":"6month","weight":-0.0706},{"period":"1year","weight":-0.0443},{"period":"ytd","weight":-0.0514}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"石四药集团有限公司,前称为利君国际医药（控股）有限公司，是一家主要从事研究、开发、制造及向医院及分销商销售药物产品的投资控股公司。公司的产品主要包括静脉输液的成药、原料药及医用材料。该公司的产品主要包括非聚氯乙烯软袋输液、聚丙烯塑瓶输液和玻璃瓶输液。该公司的产品还包括盐酸倍他司汀、盐酸氨溴索、盐酸罗哌卡因和多索茶碱以及原料药，包括咖啡因、茶碱、氨茶碱、甲硝唑和硝苯地平。","yearOnYearQuotes":[{"month":1,"riseRate":0.52381,"avgChangeRate":0.008129},{"month":2,"riseRate":0.52381,"avgChangeRate":0.020564},{"month":3,"riseRate":0.666667,"avgChangeRate":0.079144},{"month":4,"riseRate":0.47619,"avgChangeRate":0.030994},{"month":5,"riseRate":0.47619,"avgChangeRate":0.01054},{"month":6,"riseRate":0.47619,"avgChangeRate":0.060529},{"month":7,"riseRate":0.380952,"avgChangeRate":-0.020932},{"month":8,"riseRate":0.380952,"avgChangeRate":-0.010111},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.041628},{"month":10,"riseRate":0.428571,"avgChangeRate":-0.003216},{"month":11,"riseRate":0.65,"avgChangeRate":0.086395},{"month":12,"riseRate":0.5,"avgChangeRate":-0.009036}],"exchange":"SEHK","name":"石四药集团","nameEN":"SSY GROUP"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"石四药集团(02005)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供石四药集团(02005)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"石四药集团,02005,石四药集团股票,石四药集团股票老虎,石四药集团股票老虎国际,石四药集团行情,石四药集团股票行情,石四药集团股价,石四药集团股市,石四药集团股票价格,石四药集团股票交易,石四药集团股票购买,石四药集团股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"石四药集团(02005)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供石四药集团(02005)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}